BioCentury
ARTICLE | Clinical News

CGC-11047: Phase I started

November 13, 2006 8:00 AM UTC

Cellgate began an open-label, dose-escalation, U.S. Phase I trial in 15 patients who will receive CGC-11047 subconjunctivally. ...